Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Portfolio Pulse from
Arbutus Biopharma's phase 2a trial of Imdusiran achieved a functional cure in 25% of Hepatitis B patients, leading to the development of a phase 2b trial. The company is also developing an oral PD-L1 inhibitor, AB-101, with data expected in 2025. The Hepatitis B market is projected to reach $6.65 billion by 2034.
January 07, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arbutus Biopharma's Imdusiran achieved a 25% functional cure rate in Hepatitis B patients, prompting a phase 2b trial. The company is also working on AB-101, with data expected in 2025.
The positive results from the phase 2a trial of Imdusiran are significant, as they show a 25% cure rate, which is a promising development for Arbutus Biopharma. This success leads to the advancement to a phase 2b trial, indicating potential future revenue growth. Additionally, the development of AB-101 and the expected data in 2025 could further enhance the company's product pipeline and market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100